Baxter touts blood purification efficiency in EBP studies

Baxter (NYSE:BAX) today released data from 2 studies on extracorporeal blood purification studies, touting the blood purification method’s ability to remove harmful molecules linked to inflammation. Extracorporeal blood purification takes place outside the body, with blood passing through a membrane within an extracorporeal circuit to filter harmful molecules and waste products out of the blood, the company said. The clean blood is then returned to the body. The method is commonly used for patients with kidney injuries. Data from the studies was presented at the American Society of Nephrology’s annual Kidney Week in Chicago. ”Baxter continues to build on its commitment to contribute meaningful research to advance acute and chronic blood therapies. This exploratory research adds to the body of knowledge in an important area that is not fully understood – the treatment of inflammation-related conditions in chronic kidney disease and critically ill ICU patients,” medical affairs veep Dr. Dheerendra Kommala said in a prepared statement. The 1st in vitro study examined EBP’s ability to remove inflammatory and auto-immune response stimulating cytokines, including IL-6, looking to reduce inflammation in end-stage renal disease patients, which can lead to complications such as cardiovascular disease. Data from the study indicated that the EBP membranes were able to remove IL-6 and other cell activating molecules, with more porous mid-cut off and high-...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Blood Management Clinical Trials Baxter Source Type: news